Antibiotic Resistance Market Size, Share & Trends Report

Antibiotic Resistance Market Size, Share & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class (Oxazolidinones, Lipoglycopeptides), By Mechanism Of Action, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030

Report ID: GVR-2-68038-663-9
Number of Pages: 180
Format: Electronic (PDF)

Historical Range: 2018 - 2021
Industry:Healthcare

Market Segmentation

Antibiotic Resistance Disease Outlook (Revenue, USD Million, 2018 - 2030)
- cUTI
- CDI
- ABSSSI
- HABP
- CABP
- cIAI
- BSI
Antibiotic Resistance Pathogen Outlook (Revenue, USD Million, 2018 - 2030)
- E. coli
- K. pneumoniae
- P. aeruginosa
- S. aureus
- baumannii
- S. pneumoniae
- H. influenzae
- difficile
- E. faecium
Antibiotic Resistance Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Combination therapies
- Cephalosporins
- Others
Antibiotic Resistance Mechanism of Action Outlook (Revenue, USD Million, 2018 - 2030)
- Protein Synthesis Inhibitors
- Cell Wall Synthesis Inhibitors
- RNA Synthesis Inhibitors
- DNA Synthesis Inhibitors
- Others
Antibiotic Resistance Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Antibiotic Resistance Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Antibiotic Resistance Market, by Disease
    - cUTI
    - CDI
    - ABSSSI
    - HABP
    - CABP
    - cIAI
    - BSI
  - North America Antibiotic Resistance Market, by Pathogen
    - E. coli
    - K. pneumoniae
    - P. aeruginosa
    - S. aureus
    - baumannii
    - S. pneumoniae
    - H. influenzae
    - difficile
    - E. faecium
  - North America Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Combination therapies
    - Cephalosporins
    - Others
  - North America Antibiotic Resistance Market, by Mechanism of Action
    - Protein Synthesis Inhibitors
    - Cell Wall Synthesis Inhibitors
    - RNA Synthesis Inhibitors
    - DNA Synthesis Inhibitors
    - Others
  - North America Antibiotic Resistance Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - The U.S.
    - U.S. Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - U.S. Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - U.S. Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - U.S. Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - U.S. Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Canada
    - Canada Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Canada Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Canada Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Canada Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Canada Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Europe
  - Europe Antibiotic Resistance Market, by Disease
    - cUTI
    - CDI
    - ABSSSI
    - HABP
    - CABP
    - cIAI
    - BSI
  - Europe Antibiotic Resistance Market, by Pathogen
    - E. coli
    - K. pneumoniae
    - P. aeruginosa
    - S. aureus
    - baumannii
    - S. pneumoniae
    - H. influenzae
    - difficile
    - E. faecium
  - Europe Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Combination therapies
    - Cephalosporins
    - Others
  - Europe Antibiotic Resistance Market, by Mechanism of Action
    - Protein Synthesis Inhibitors
    - Cell Wall Synthesis Inhibitors
    - RNA Synthesis Inhibitors
    - DNA Synthesis Inhibitors
    - Others
  - Europe Antibiotic Resistance Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - UK
    - UK Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - UK Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - UK Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - UK Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - UK Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Germany
    - Germany Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Germany Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Germany Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Germany Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Germany Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - France
    - France Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - France Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - France Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - France Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - France Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Spain
    - Spain Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Spain Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Spain Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Spain Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Spain Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Italy
    - Italy Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - 抗生素耐药性意大利市场,由病原体
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Italy Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Italy Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Italy Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Denmark
    - Denmark Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Denmark Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Denmark Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Denmark Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Denmark Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Sweden
    - Sweden Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Sweden Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Sweden Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Sweden Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Sweden Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Norway
    - Norway Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Norway Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Norway Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Norway Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Norway Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Asia Pacific
  - Asia Pacific Antibiotic Resistance Market, by Disease
    - cUTI
    - CDI
    - ABSSSI
    - HABP
    - CABP
    - cIAI
    - BSI
  - Asia Pacific Antibiotic Resistance Market, by Pathogen
    - E. coli
    - K. pneumoniae
    - P. aeruginosa
    - S. aureus
    - baumannii
    - S. pneumoniae
    - H. influenzae
    - difficile
    - E. faecium
  - Asia Pacific Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Combination therapies
    - Cephalosporins
    - Others
  - Asia Pacific Antibiotic Resistance Market, by Mechanism of Action
    - Protein Synthesis Inhibitors
    - Cell Wall Synthesis Inhibitors
    - RNA Synthesis Inhibitors
    - DNA Synthesis Inhibitors
    - Others
  - Asia Pacific Antibiotic Resistance Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - Japan
    - Japan Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Japan Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Japan Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Japan Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Japan Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - China
    - China Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - China Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - China Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - China Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - China Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - India
    - India Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - India Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - India Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - India Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - India Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - South Korea
    - South Korea Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - South Korea Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - South Korea Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - South Korea Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - South Korea Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Australia
    - Australia Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Australia Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Australia Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Australia Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Australia Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Thailand
    - Thailand Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Thailand Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Thailand Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Thailand Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Thailand Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Latin America
  - Latin America Antibiotic Resistance Market, by Disease
    - cUTI
    - CDI
    - ABSSSI
    - HABP
    - CABP
    - cIAI
    - BSI
  - Latin America Antibiotic Resistance Market, by Pathogen
    - E. coli
    - K. pneumoniae
    - P. aeruginosa
    - S. aureus
    - baumannii
    - S. pneumoniae
    - H. influenzae
    - difficile
    - E. faecium
  - Latin America Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Combination therapies
    - Cephalosporins
    - Others
  - Latin America Antibiotic Resistance Market, by Mechanism of Action
    - Protein Synthesis Inhibitors
    - Cell Wall Synthesis Inhibitors
    - RNA Synthesis Inhibitors
    - DNA Synthesis Inhibitors
    - Others
  - Latin America Antibiotic Resistance Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - Brazil
    - Brazil Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Brazil Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Brazil Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Brazil Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Brazil Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Mexico
    - Mexico Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Mexico Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Mexico Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Mexico Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Mexico Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Argentina
    - Argentina Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Argentina Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Argentina Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Argentina Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Argentina Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
- Middle East & Africa
  - Middle East & Africa Antibiotic Resistance Market, by Disease
    - cUTI
    - CDI
    - ABSSSI
    - HABP
    - CABP
    - cIAI
    - BSI
  - Middle East & Africa Antibiotic Resistance Market, by Pathogen
    - E. coli
    - K. pneumoniae
    - P. aeruginosa
    - S. aureus
    - baumannii
    - S. pneumoniae
    - H. influenzae
    - difficile
    - E. faecium
  - Middle East & Africa Antibiotic Resistance Market, by Drug Class
    - Oxazolidinones
    - Lipoglycopeptides
    - Tetracyclines
    - Combination therapies
    - Cephalosporins
    - Others
  - Middle East & Africa Antibiotic Resistance Market, by Mechanism of Action
    - Protein Synthesis Inhibitors
    - Cell Wall Synthesis Inhibitors
    - RNA Synthesis Inhibitors
    - DNA Synthesis Inhibitors
    - Others
  - Middle East & Africa Antibiotic Resistance Market, by Distribution Channel
    - Hospital Pharmacies
    - Retail Pharmacies
    - Online Pharmacies
  - South Africa
    - South Africa Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - South Africa Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - South Africa Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - South Africa Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - South Africa Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Saudi Arabia
    - Saudi Arabia Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Saudi Arabia Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Saudi Arabia Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Saudi Arabia Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Saudi Arabia Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - Kuwait
    - Kuwait Antibiotic Resistance Market, by Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - Kuwait Antibiotic Resistance Market, by Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - Kuwait Antibiotic Resistance Market, by Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - Kuwait Antibiotic Resistance Market, by Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - Kuwait Antibiotic Resistance Market, by Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies
  - UAE
    - 抗生素耐药性阿联酋市场,Disease
      - cUTI
      - CDI
      - ABSSSI
      - HABP
      - CABP
      - cIAI
      - BSI
    - 抗生素耐药性阿联酋市场,Pathogen
      - E. coli
      - K. pneumoniae
      - P. aeruginosa
      - S. aureus
      - baumannii
      - S. pneumoniae
      - H. influenzae
      - difficile
      - E. faecium
    - 抗生素耐药性阿联酋市场,Drug Class
      - Oxazolidinones
      - Lipoglycopeptides
      - Tetracyclines
      - Combination therapies
      - Cephalosporins
      - Others
    - 抗生素耐药性阿联酋市场,Mechanism of Action
      - Protein Synthesis Inhibitors
      - Cell Wall Synthesis Inhibitors
      - RNA Synthesis Inhibitors
      - DNA Synthesis Inhibitors
      - Others
    - 抗生素耐药性阿联酋市场,Distribution Channel
      - Hospital Pharmacies
      - Retail Pharmacies
      - Online Pharmacies

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
乐鱼体育手机网站入口
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report -free of charge- including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read ourprivacy policy.